Research and Markets (http://www.researchandmarkets.com/research/7tmcjv/bone) has announced the addition of the "Bone Cancer-Pipeline Insights, 2016" report to their offering.

Bone Cancer-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Bone Cancer. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Bone Cancer.

The report also assesses the Bone Cancer therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Bone Cancer
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Bone Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Bone Cancer and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Bone Cancer Overview
  2. Bone Cancer Pipeline Therapeutics
  3. Bone Cancer Therapeutics under Development by Companies
  4. Bone Cancer Filed and Phase III Products
  5. Comparative Analysis
  6. Bone Cancer Phase II Products
  7. Bone Cancer Phase I and IND Filed Products
  8. Bone Cancer Discovery and Pre-Clinical Stage Products
  9. Bone Cancer - Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Bone Cancer - Discontinued Products
  15. Bone Cancer - Dormant Products
  16. Companies Involved in Therapeutics Development for Bone Cancer

For more information visit http://www.researchandmarkets.com/research/7tmcjv/bone